It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
"Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution."
"The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies, (...)
"While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."
The company's U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report.
originally posted by: VengefulGhost
nope theyd lose tons of money if they actually cured patients .
originally posted by: buddah6
originally posted by: VengefulGhost
nope theyd lose tons of money if they actually cured patients .
I have had the misfortune of dealing with the medical community for the last twenty six years.
originally posted by: VengefulGhost
nope theyd lose tons of money if they actually cured patients .
Just curious how much have you paid back into the system in those 31 years?